Alfasigma S.p.A. signed a letter of intent to acquire Filgotinib business of Galapagos NV (ENXTAM:GLPG) for approximately ?170 million on October 30, 2023. The transaction consist of ?50 million upfront payment and potential sales-based milestone payments ?120 million. Transaction is expected to close in the first quarter of 2024, subject to customary closing conditions. The completion of the intended transaction is subject to the execution of a definitive agreement and customary conditions. Alfasigma S.p.A. signed an agreement to acquire Filgotinib business of Galapagos NV (ENXTAM:GLPG) on January 2, 2024.

Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV (ENXTAM:GLPG) on January 31, 2024. On completion of the transaction, approximately 400 Galapagos positions in 14 European countries transferred to Alfasigma to support business continuity and ongoing patient access. Michele Manto, former Chief Commercial Officer of Galapagos, also joins Alfasigma to lead the Jyseleca business. Galapagos will receive a ?50 million upfront payment, potential sales-based milestone payments totaling ?120 million and mid-single to mid-double-digit royalties on European sales. Galapagos will contribute up to ?40 million to Alfasigma by June 2025 for Jyseleca® related development activities.

Van Lanschot Kempen and Morgan Stanley served as financial advisors to Galapagos, and Baker McKenzie acted as the legal advisor to Galapagos.